Core Viewpoint - The article highlights a case of commercial bribery involving Shanghai Haiyilai Consulting Management Partnership, which engaged in unethical practices to promote a specific drug, leading to administrative penalties and potential impacts on the involved companies' reputations and operations [2][3][4][5] Group 1: Company Actions and Penalties - Shanghai Haiyilai Consulting Management Partnership was found to have paid improper benefits to a clinical doctor to influence prescription behavior for the drug "Dahansuan Sodium Injection" [2] - The company received a total service income of 868,677 yuan from Shanghai Hongjian Pharmaceutical Co., and was fined 300,000 yuan by the Shanghai Putuo District Market Supervision Administration for commercial bribery [3] - The sales promotion director of Haiyilai promised the doctor a "benefit fee" for increased prescriptions, resulting in a total transfer of 35,046 yuan over four transactions [2][3] Group 2: Implications for Related Companies - The case has implications for Hebei Changshan Biochemical Pharmaceutical Co., which is linked to the drug involved and is a publicly listed company in China [3] - The annual sales of "Dahansuan Sodium Injection" exceed 170 million yuan, with a reported 26.68% year-on-year increase in sales volume, although revenue remained stable due to price declines [3] - The National Healthcare Security Administration has established a credit evaluation system since 2020 to assess pharmaceutical companies involved in commercial bribery, which may affect Changshan Pharmaceutical's credit rating in drug procurement [4][5]

Core Viewpoint - The announcement from the Hebei Provincial Medical Supplies Procurement Center indicates that several companies are being rated as "generally" untrustworthy due to inadequate delivery services for selected products in the national centralized procurement process [1][2][3] Group 1: Companies Involved - Companies listed for potential untrustworthiness include Suzhou Terui Pharmaceutical, Sihuan Pharmaceutical, Lijun Group, Jiangxi Yongfeng Kande Pharmaceutical, Guangdong Saifeng Pharmaceutical, Beijing Fule Technology, and Beijing Beilu Pharmaceutical [1][2] - Lijun Group's voriconazole injection was selected in the eighth batch of national procurement at a price of 29.19 yuan per unit, down from a previous market price of 700-800 yuan, representing a price drop of over 90% [1] - Beilu Pharmaceutical's iopamidol injection was selected in the seventh batch of national procurement at a price of 91.3 yuan per unit, being the only contrast agent selected in that batch [1] Group 2: Regulatory Framework - The Hebei Provincial Medical Security Bureau established a credit evaluation system for drug pricing and procurement in late 2020, categorizing untrustworthy behavior into four levels: "general," "moderate," "serious," and "particularly serious" [3] - The "general" untrustworthiness rating applies to companies that fail to fulfill procurement or delivery contracts without valid reasons and do not notify procurement agencies in advance, provided it does not severely impact clinical treatment [3] - Once a company is rated as untrustworthy, the provincial procurement center will implement measures such as written warnings, risk notifications on procurement platforms, and restrictions on procurement qualifications [3] Group 3: Broader Industry Context - The issue of supply shortages is not limited to medical institutions; designated pharmacies in Hebei also face significant shortages, with 422 drugs reported as unavailable [4] - Other regions, including Liaoning, Hainan, and Guangzhou, have also reported issues with selected companies failing to deliver drugs on time since the implementation of centralized procurement policies [4] - As of May 31, 2023, 443 drug varieties had not established timely delivery relationships post-procurement, with nearly 70% of the identified varieties having a delivery rate of 0% [4] Group 4: Future Developments - By the end of 2024, 612 companies were rated as generally untrustworthy, 76 as moderately untrustworthy, 40 as seriously untrustworthy, and 7 as particularly seriously untrustworthy [5] - A new standard for credit evaluation will be implemented starting from the third quarter of 2025, simplifying the rating system from four levels to three: "untrustworthy," "seriously untrustworthy," and "particularly seriously untrustworthy" [6]